Moving your cell therapy clinical trial beyond Phase I is an exciting time, marking a significant milestone. There are many therapeutic developers working to address critical patient needs in oncology, auto-immune, regenerative medicine, and other spaces.
FDA approves Iovance’s cell therapy for melanoma, the first treatment based on tumor-infiltrating lymphocytes
An experimental approach to treating cancer more than 40 years in the making finally has a long-sought and repeatedly delayed green light from the FDA.
February 17, 2024